Trials / Completed
CompletedNCT02996305
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Healx AI · Industry
- Sex
- All
- Age
- 13 Years – 49 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety and tolerability of oral OV101 (gaboxadol) in adult and adolescent subjects with Angelman syndrome. In addition, several exploratory efficacy outcome measures will be investigated.
Detailed description
Two dosing schedules of OV101 (gaboxadol) giving as once daily or twice daily dose will be assessed against placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OV101 Regimen 1 | |
| DRUG | OV101 regimen 2 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-06-07
- Completion
- 2018-08-06
- First posted
- 2016-12-19
- Last updated
- 2025-08-03
- Results posted
- 2022-03-31
Locations
13 sites across 2 countries: United States, Israel
Source: ClinicalTrials.gov record NCT02996305. Inclusion in this directory is not an endorsement.